Trial Summary

A new clinical trial being conducted at a single centre in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NET Research Foundation (NETRF).

The goal of the proof-of-concept study is to measure the therapeutic index of 161Tb-DOTA-LM3 in comparison to the current standard treatment with 177Lu-DOTATOC in gastroenteropancreatic neuroendocrine tumours (GEP-NET).  

Damian Wild, MD, PhD, leads the current proof-of-concept trial at University Hospital, Basel. The study will enrol up to 16 patients who have metastasized and non-secreting GEP-NETs (grade 1 and 2). Patients will be randomized into two treatment groups. In the first phase of the study, one test injection with 161Tb-DOTA-LM3 and 177Lu-DOTATOC will be administered in both randomized groups in a different order, followed by approximately 3 cycles of PRRT in both groups. In the second phase, two test injections with 161Tb-DOTA-LM3 with different peptide amounts will be administered in both treatment groups in a different order, followed by approximately two cycles of PRRT with 161Tb-DOTA-LM3.

Additional information on the study can be found at the link below.  Interested participants should talk to their treatment team about eligibility and determine if the study is aligned with their treatment goals.  I also draw your attention to the inclusion and exclusion criteria in the clinical trials document linked below.